Teleflex (TFX) AI Stock Analysis

• Market Cap: $4.96B
• Dividend Yield: 1.11%
• Average Volume (3M): 938.56K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.51
• Revenue Growth: 5.43%
• EPS Growth: -245.18%
• Country: US
• Employees: 14,100
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.93
• Shares Outstanding: 44,194,410
• 10 Day Avg. Volume: 864,084
• 30 Day Avg. Volume: 938,559
• PEG Ratio: -1.49
• Price to Book (P/B): 1.95
• Price to Sales (P/S): 2.74
• P/FCF Ratio: 16.37
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: 2.38
• Enterprise Value/Gross Profit: 4.24
• Enterprise Value/Ebitda: 52.27
• 1Y Price Target: $127.00
• Price Target Upside: 13.50% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 6
• EPS Forecast (FY): 14.05
• Revenue Forecast (FY): $3.41B

• Rating: 50 Neutral
• Price Target: $112.00 ▲(0.10% Upside)
• Action: Reiterated Date: 02/26/26
• Date: Action: Reiterated 02/26/26

The score is held down primarily by deteriorated TTM financials (sharp revenue decline, large net loss, and negative free cash flow). The earnings outlook is moderately supportive due to guided mid-single-digit growth and clear portfolio actions, but near-term margin/EPS headwinds and execution risk temper confidence. Technicals are mixed with only early signs of improvement, and valuation support is limited by a negative P/E and a modest dividend yield.

Positive Factors

Low Financial Leverage

Teleflex’s very low debt-to-equity ratio signals a strong capital structure and financial flexibility. Over the next several months this supports strategic choices—funding buybacks, targeted M&A, or debt reduction—while lowering insolvency risk and preserving negotiating power with suppliers and payors.

Proceeds and Share Repurchase Capacity

The planned $2.03B disposals and $1B buyback authorization materially increase optionality: they free capital to shrink non-core exposure, accelerate balance-sheet repair, and return cash to shareholders. This structural capital redeployment can sharpen focus on higher‑acuity franchises and fund reinvestment.

Top-line Growth and Acquisition Integration

Sustained revenue expansion and on‑track integration of the Vascular Intervention business indicate durable growth drivers beyond cyclicality. New product market entries (Barrigel in Japan) and successful M&A execution expand addressable markets and diversify revenue streams over the medium term.

Negative Factors

Weak Profitability Metrics

Persistent negative net margins and ROE highlight structural profitability challenges that limit internal funding for R&D, capex and shareholder returns. Unless operating efficiency or product mix improves, margins could impede long‑term free cash flow generation and strategic reinvestment capacity.

Declining Free Cash Flow Growth

A notable drop in free cash flow growth reduces financial headroom for capex, acquisitions, and buybacks despite low leverage. Over the next several months this constrains management’s ability to execute on strategic redeployments and may force prioritization between growth investments and shareholder returns.

Leadership Transition & Execution Risk

A CEO change amid a major portfolio transformation raises execution risk: continuity on strategy, integration of divestitures, and delivery against guidance can be disrupted. Interim leadership and a search process can slow decision making and extend uncertainty during critical restructuring and divestiture execution.

Teleflex Business Overview & Revenue Model

Company Description

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

How the Company Makes Money

Teleflex generates revenue primarily through the sale of its medical devices and technologies across multiple healthcare sectors. The company's key revenue streams include its vascular access products, which are critical for various medical procedures, as well as its anesthesia and respiratory care offerings. Teleflex also benefits from partnerships with healthcare providers and institutions, enabling it to gain insights into market needs and drive innovation. Additionally, the company invests in research and development to expand its product portfolio, which further enhances its revenue potential. Sales are made through direct sales teams and distributors, ensuring broad market access.

Teleflex Financial Statement Overview

Summary

TTM fundamentals weakened sharply: revenue fell to about $2.0B and profitability swung to a large net loss (about -$906M), alongside a steep drop in operating cash flow (~$96M) and negative free cash flow (~-$29M). The balance sheet still shows meaningful equity (~$3.12B) and reduced absolute debt, but negative ROE and weaker cash generation reduce financial quality and visibility.

Income Statement

Results deteriorated sharply in TTM (Trailing-Twelve-Months): revenue fell to ~$2.0B (down ~37.5%) and profitability swung deeply negative (net income about -$906M, net margin ~-10%). This is a major break from the prior multi-year pattern of solid gross margins (~52–56%) and positive earnings (2020–2024), suggesting a large non-recurring hit and/or significant operating pressure. While gross margin remains relatively resilient in TTM (~53.7%), the collapse in earnings and the steep revenue decline meaningfully weaken the income statement profile versus recent years.

Balance Sheet

The balance sheet shows moderate leverage and a sizable equity base, but it weakened in TTM (Trailing-Twelve-Months). Debt fell sharply (to ~$184M from ~$1.76B in 2024), yet debt-to-equity is reported higher in TTM (~0.72 vs ~0.41 in 2024), implying either reporting differences or equity/structure impacts that reduce clarity. Total assets remained large (~$6.95B) and equity (~$3.12B) provides a buffer, but returns to shareholders turned negative in TTM (return on equity ~-8%), reflecting the earnings drawdown and lowering overall balance-sheet quality despite the reduced absolute debt.

Cash Flow

Cash generation weakened materially in TTM (Trailing-Twelve-Months). Operating cash flow dropped to ~$96M from ~$636M in 2024, and free cash flow turned negative (about -$29M) after being strongly positive in prior years. Cash conversion also softened: operating cash flow covered only ~51% of net income in TTM, and the negative free cash flow raises concerns around near-term funding flexibility and reinvestment capacity. The positive history of strong free cash flow (2020–2024) is a support, but the current TTM step-down is significant.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.99B	3.05B	2.97B	2.79B	2.81B	2.54B
Gross Profit	1.12B	1.70B	1.65B	1.53B	1.55B	1.32B
EBITDA	90.89M	433.62M	761.21M	730.77M	853.80M	651.48M
Net Income	-905.64M	69.67M	356.33M	363.14M	485.37M	335.32M
Balance Sheet
Total Assets	6.95B	7.10B	7.53B	6.93B	6.87B	7.15B
Cash, Cash Equivalents and Short-Term Investments	378.56M	306.16M	222.85M	292.03M	445.08M	375.88M
Total Debt	184.21M	1.76B	1.93B	1.83B	1.97B	2.56B
Total Liabilities	3.82B	2.82B	3.09B	2.91B	3.12B	3.82B
Stockholders Equity	3.12B	4.28B	4.44B	4.02B	3.75B	3.34B
Cash Flow
Free Cash Flow	-28.66M	509.31M	419.20M	262.95M	579.80M	345.71M
Operating Cash Flow	95.94M	635.74M	510.64M	342.14M	651.42M	436.41M
Investing Cash Flow	-48.85M	-99.36M	-621.23M	-257.94M	156.74M	-837.78M
Financing Cash Flow	613.62M	-421.93M	38.54M	-217.51M	-715.82M	455.16M

Teleflex Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 111.89
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TFX, the sentiment is Neutral. The current price of 111.89 is above the 20-day moving average (MA) of 107.56, below the 50-day MA of 112.48, and below the 200-day MA of 118.68, indicating a neutral trend. The MACD of 0.72 indicates Negative momentum. The RSI at 55.03 is Neutral, neither overbought nor oversold. The STOCH value of 67.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TFX.

Teleflex Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LMAT	75 Outperform	$2.06B	39.05	15.02%	0.95%	13.07%	27.98%
MMSI	68 Neutral	$4.89B	37.27	8.30%	―	11.49%	-2.89%
HAE	61 Neutral	$2.87B	17.13	19.30%	―	-2.45%	41.50%
BLCO	60 Neutral	$6.53B	-18.25	-4.69%	―	6.23%	17.53%
ICUI	57 Neutral	$3.76B	6,305.69	-0.35%	―	-0.81%	93.27%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TFX	50 Neutral	$4.96B	-15.21	-7.90%	1.11%	5.43%	-245.18%

Teleflex Corporate Events

Teleflex Launches Multi-Year Restructuring to Support Divestitures

On February 23, 2026, Teleflex’s board approved a multi‑year restructuring tied to its planned strategic divestitures, aiming to realign its global organization and supply chain, cut stranded costs and rationalize capital assets, largely through workforce reductions. The program, expected to be substantially complete by mid‑2028, carries estimated restructuring and related charges of $31 million to $37 million, mostly cash outlays, and is projected to deliver annual pre‑tax savings of $48 million to $52 million once fully implemented, beginning to benefit results in 2026.

The company reported 2025 revenue from continuing operations of $1.99 billion, up more than 17% year on year, with adjusted EPS also improving, and issued 2026 guidance that builds in $90 million of stranded costs while excluding anticipated offsets from transition and manufacturing services tied to the divested units. Management framed the restructuring and divestitures as part of a broader portfolio transformation, with the two planned divestiture deals expected to close in the second half of 2026 and provide after‑tax proceeds earmarked largely for share repurchases and debt reduction, positioning Teleflex to enhance profitability and long‑term shareholder value after the transition period.

The most recent analyst rating on (TFX) stock is a Hold with a $116.00 price target. To see the full list of analyst forecasts on Teleflex stock, see the TFX Stock Forecast page.

Teleflex completes CEO transition and separation agreement

Teleflex announced that Liam J. Kelly departed from his roles as president and chief executive officer effective at the end of the day on January 7, 2026, and subsequently resigned from the board on January 23, 2026, marking a completed leadership transition at the company. In connection with his departure, Teleflex entered into a separation agreement on January 23, 2026, under which Kelly will receive the benefits associated with a termination without cause as outlined in his existing severance agreement, including lump-sum outplacement benefits and treatment of outstanding equity awards, contingent upon his release of claims in favor of the company and its affiliates, clarifying the financial and governance implications of the executive change for stakeholders.

The most recent analyst rating on (TFX) stock is a Hold with a $106.00 price target. To see the full list of analyst forecasts on Teleflex stock, see the TFX Stock Forecast page.

Teleflex Announces CEO Transition Amid Strategic Portfolio Shift

Teleflex announced a major leadership transition effective January 7–8, 2026, with long-time Chairman, President and CEO Liam Kelly departing and board member Stuart Randle, a veteran medical device executive with more than 35 years’ industry experience and a Teleflex director since 2009, stepping in as interim president and CEO. Lead independent director Stephen Klasko was appointed independent chair of the board, while the board engaged Spencer Stuart to search for a permanent chief executive, and Randle’s interim role was formalized through a short-term employment letter that includes a substantial monthly stipend and a $1.5 million restricted stock grant; Kelly, subject to executing a release of claims, is eligible for severance and equity vesting under his existing agreements. The leadership reshuffle comes as Teleflex pursues a strategic transformation following the announced sale of its Acute Care, Interventional Urology and OEM businesses to sharpen its focus on core critical care and high-acuity markets, and it coincided with a downgrade to preliminary full-year 2025 revenue expectations to $3.270 billion–$3.278 billion from prior guidance of $3.305 billion–$3.320 billion, reflecting softer demand for intra-aortic balloon pumps and catheters in the U.S. and Asia, OEM order delays and lower volumes in certain portfolio segments, developments that underscore both operational headwinds and the execution risk around its portfolio repositioning for investors and other stakeholders.

The most recent analyst rating on (TFX) stock is a Hold with a $135.00 price target. To see the full list of analyst forecasts on Teleflex stock, see the TFX Stock Forecast page.

Teleflex Announces $2.03 Billion Business Sale Agreements

On December 9, 2025, Teleflex announced agreements to sell its Acute Care, Interventional Urology, and Original Equipment Manufacturing (OEM) businesses for a total of $2.03 billion in cash. The transactions are expected to close in the second half of 2026, subject to regulatory approvals. The proceeds will be used for share repurchases and debt reduction, enhancing Teleflex’s financial flexibility and allowing it to focus on its core critical care and high acuity hospital markets. The company’s Board of Directors has also authorized a $1 billion share repurchase program, reflecting confidence in Teleflex’s strategic direction and growth potential.

The most recent analyst rating on (TFX) stock is a Hold with a $127.00 price target. To see the full list of analyst forecasts on Teleflex stock, see the TFX Stock Forecast page.